Back to results
US 2017/0304437 A1Published application
Bispecific molecules capable of specifically binding to both ctla-4 and cd40
AssigneeAlligator Bioscience AB
InventorsPeter ELLMARK, Christina FUREBRING, Per NORLEN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to bispecific molecules that specifically bind to both CD40 and CTLA-4, and in particular to both human CD40 and human CTLA-4.
Claims25
A polypeptide capable of specifically binding to both CTLA-4 and CD40, said polypeptide comprising B1 and B2, wherein:
- B1 is an antibody, or antigen binding fragment thereof, specific for CD40;
- and
- B2 is a polypeptide binding domain specific for CTLA-4, which comprises or consists of:
- i) the amino acid sequence of SEQ ID NO:
- 3;
- or
- ii) an amino acid sequence in which at least one amino acid is changed when compared to the amino acid sequence of SEQ ID NO:
- 3 provided that said binding domain binds to human CTLA-4 with higher affinity than wild-type human CD86.
5 more elements
9-10. (canceled)
(canceled)
A method of treating or preventing a disease or condition in an individual, the method comprising administering to an individual a polypeptide capable of specifically binding to both CTLA-4 and CD40, said polypeptide comprising B1 and B2, wherein:
- B1 is an antibody, or antigen binding fragment thereof, specific for CD40;
- and
- B2 is a polypeptide binding domain specific for CTLA-4, which comprises or consists of:
- i) the amino acid sequence of SEQ ID NO:
- 3;
- or
- ii) an amino acid sequence in which at least one amino acid is changed when compared to the amino acid sequence of SEQ ID NO:
- 3 provided that said binding domain binds to human CTLA-4 with higher affinity than wild-type human CD86.
5 more elements
(canceled)
Dependencies are inferred from the claim text.